Pharmaceutical News and Articles

Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

GSK plc (LSE NYSE GSK) today announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depem

Indivior Announces FDA Approval of Label Changes for Sublocade (buprenorphine extended-release) Injection

Monthly News Roundup - February 2025

FDA Updates Izervay Label to Lengthen Treatment Duration for Geographic Atrophy Izervay (avacincaptad pegol) from Astellas is now FDA-approved without a limitat

How To Talk to Your Child About a Cancer Diagnosis

Learning that your child has cancer is overwhelming, and talking to them about it can feel just as difficult. But experts stress that open and honest communicat

How to Treat Spring Allergies: A Graduated Approach

Spring brings warmer weather, but for allergy sufferers, it also means sneezing, wheezing and itchy eyes. Instead of enjoying the season, you may be battling co

Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study

CHICAGO February 25, 2025 Emalex Biosciences announced positive topline data from its Phase 3 registrational study of ecopipam, a novel dopamine-1 receptor anta

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Pyxis Oncology, Inc. (Nasdaq PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that the U.

Camizestrant Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in 1st-Line Advanced HR-Positive Breast Cancer with an Emergent ESR1 Tumor Mutation in SERENA-6 Phase III Trial

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca s camizestrant in combination with a cyclin-

BlueRock Therapeutics Receives FDA Fast Track Designation for OpCT-001 for the Treatment of Primary Photoreceptor Diseases

Berlin, Germany, and Cambridge, MA, USA February 27, 2025 Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidia

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma